Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
J Psychiatr Res ; 171: 30-37, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38241967

RESUMO

BACKGROUND: Childhood trauma is intimately related with suicidal behaviour. Patients who have suffered childhood trauma develop impaired Reflective Functioning (RF), which refers to the capacity to understand ourselves and others in terms of intentional mental states. An improvement in RF has been associated with a reduction in suicidal attempts, but the mediating role of RF between childhood trauma and suicidal behaviour has not been addressed so far. OBJECTIVE: We aim to examine the potential mediating effect of RF among childhood trauma and suicide attempts. METHOD: We included 748 patients who had attempted suicide at least once. They were asked to complete the Reflective Functioning Questionnaire (RFQ-8), the Columbia-Suicide Severity Rating scale (CSSRS), and the Childhood Trauma Questionnaire-Short Form (CTQ-SF). We conducted linear regressions by simple mediating model to examine the role of RF in the indirect association between childhood trauma and the number of suicide attempts. RESULTS: Our results show significant indirect effects through hypo and hypermentalizing between Emotional Abuse (EA) and Sexual Abuse (SA) in childhood and the number of suicide attempts in lifetime. These results indicate that ineffective RF significantly mediates the association between childhood trauma and suicidality. CONCLUSION: This is the first study supporting the mediational role of RF in the relationship between EA and SA, and the number of suicide attempt in lifetime. These findings have important implications for reducing suicide rates and preventing future re-attempts. Further studies analysing this mediating role and focusing efforts on increasing RF-based interventions are required.


Assuntos
Experiências Adversas da Infância , Testes Psicológicos , Tentativa de Suicídio , Humanos , Autorrelato , Ideação Suicida , Fatores de Risco
2.
Opt Express ; 31(4): 5414-5425, 2023 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-36823822

RESUMO

We report a directly modulated distributed feedback laser operating in gain-switching mode for preparing the coherent states required for the Gaussian-modulated coherent-state (GMCS) continuous-variable quantum key distribution (CV-QKD) protocol. The proposed single-component quantum transmitter design eliminates the need for external modulators, decreasing the complexity of GMCS CV-QKD systems. The experimental results demonstrate a potential asymptotic secret key rate value of 2.63 Mbps over an 11-km fiber link, making the directly modulated GMCS transmitter particularly suitable for metropolitan optical networks where compactness, robustness, and low cost are key desirable features.

3.
Opt Express ; 29(10): 14815-14827, 2021 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-33985195

RESUMO

We present a versatile transmitter capable of performing both discrete variable and continuous variable quantum key distribution protocols (DV-QKD and CV-QKD, respectively). Using this transmitter, we implement a time-bin encoded BB84 DV-QKD protocol over a physical quantum channel of 47 km and a GG02 CV-QKD protocol with true local oscillator over a 10.5 km channel, achieving secret key rates of 4.1 kbps and 1 Mbps for DV- and CV-QKD, respectively. The reported transmitter scheme is particularly suitable for re-configurable optical networks where the QKD protocol is selected to optimize the performance according to the parameters of the links.

4.
Eur Neuropsychopharmacol ; 29(1): 76-97, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30420190

RESUMO

Clinical and epidemiological research suggests that behavioral addictions (BA) are associated with a wide range of psychiatric disorders. However, the relationship between BA and bipolar disorders (BD) has not been thoroughly explored. The aim of this systematic review was to critically summarize and evaluate the current available evidence regarding a possible association between BA and BD. A systematic review of major electronic databases according to PRISMA guidelines was conducted from inception to 31st December 2017. We sought quantitative studies data concerning prevalence of comorbidity, features and treatment related to BA-BD comorbidity. Data were narratively synthesized. Of the 1250 studies returned from the search, a total of 28 articles were included in this review. BA may be overrepresented in BD samples, and the other way around. Pathological gambling and kleptomania were the most prevalent conditions followed by compulsive buying, compulsive sexual behavior and internet addiction. BA was also associated with other mood disorders, anxiety disorders and substance use disorder. BD-BA comorbidity was related with more severe course of illness. Studies on treatment strategies for BD-BA comorbidity are rather limited; only one randomized controlled trial that fulfilled inclusion criteria was identified. Methodological heterogeneity in terms of design and results among studies was found. BD-BA commonly co-occurs although there is a need for rigorous studies. Routine screening and adequate assessment may be helpful in BD patients to identify individuals at risk for BA and to effectively manage the complex consequences associated with BA-BD comorbidity.


Assuntos
Transtornos de Ansiedade/epidemiologia , Comportamento Aditivo/epidemiologia , Transtorno Bipolar/epidemiologia , Transtornos do Humor/epidemiologia , Comorbidade , Humanos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia
5.
Braz J Med Biol Res ; 51(9): e7427, 2018 Jun 25.
Artigo em Inglês | MEDLINE | ID: mdl-29947650

RESUMO

Genetic and functional aberrations of guanine nucleotide-binding protein, alpha stimulating (GNAS), aryl hydrocarbon receptor interacting protein (AIP), and pituitary tumor transforming gene (PTTG) are among the most prominent events in pituitary tumorigenesis. A cohort of Brazilian patients with somatotropinomas (n=41) and non-functioning pituitary adenomas (NFPA, n=21) from a single tertiary-referral center were evaluated for GNAS and AIP mutations and gene expression of AIP and PTTG. Results were compared to the clinical and biological (Ki67 and p53 expression) characteristics of tumors and their response to therapy, if applicable. Genetic analysis revealed that 27% of somatotropinomas and 4.8% of NFPA harbored GNAS mutations (P=0.05). However, no differences were observed in clinical characteristics, tumor extension, response to somatostatin analog therapy, hormonal/surgical remission rates, Ki67 index, and p53 expression between mutated and non-mutated somatotropinomas patients. PTTG overexpression (RQ mean=10.6, min=4.39, max=11.9) and AIP underexpression (RQ mean=0.56, min=0.46-max=0.92) were found in virtually all cases without a statistically significant relationship with clinical and biological tumor features. No patients exhibited somatic or germline pathogenic AIP mutations. In conclusion, mutations in GNAS and abnormal PTTG and AIP expression had no impact on tumor features and treatment outcomes in this cohort. Our data support some previous studies and point to the need for further investigations, probably involving epigenetic and transcriptome analysis, to improve our understanding of pituitary tumor behavior.


Assuntos
Adenoma/genética , Mutação em Linhagem Germinativa/genética , Adenoma Hipofisário Secretor de Hormônio do Crescimento/genética , Neoplasias Hipofisárias/genética , Adenoma/patologia , Adulto , Brasil , Carcinogênese , Transformação Celular Neoplásica , Estudos de Coortes , DNA de Neoplasias , Feminino , Marcadores Genéticos , Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia , Humanos , Peptídeos e Proteínas de Sinalização Intracelular , Masculino , Pessoa de Meia-Idade , Hipófise/patologia , Neoplasias Hipofisárias/patologia
6.
J Affect Disord ; 228: 153-159, 2018 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-29248821

RESUMO

BACKGROUND: The concept of well-being which focuses on positive emotions has received increased research attention. However, a consensus definition of this term is lacking. The Well-Being Index scale (WHO-5) is a generic, self-report scale that contains five Likert-type items to evaluate psychological well-being. This construct may provide a relevant outcome in bipolar disorder (BD) research and care beyond the rating of mood symptoms. Thus, in the current study, the psychometric properties of the WHO-5 Spanish version were assessed in a sample of euthymic patients with BD. METHODS: Patients with BD- I and BD-II and healthy controls completed the Well-Being Index (WHO-5) together with an assessment of depressive (Hamilton Depression Rating Scale-17; HAM-D) and manic symptoms (Young Mania Rating Scale; YMRS); and a measure of psychosocial functioning (Functioning Assessment Short Test; FAST). Internal consistency reliability was measured through Cronbach's alpha. Test-retest reliability was calculated comparing the WHO-5 total score at baseline and after 10 days of the first administration. To assess the structure of the scale, a principal component analysis (PCA) was carried out. Correlations between the WHO-5, HAM-D, YMRS and FAST were calculated. Finally, a t-test for independent samples was applied to compare the WHO-5 total score in the patient and control groups. RESULTS: A total of 104 patients with BD and 40 healthy controls were included in this study. A Chronbach's alpha of 0.83 indicated acceptable internal consistency. A paired sample t-test revealed no significant differences between WHO-5 total score at baseline and at follow-up (tn = - 0.72; df = 15; p = 0.48). The PCA provided a single factor solution that accounted for 59.74% of the variation in WHO-5. Test-retest reliability was high (r = 0.83; p < 0.001). Moderate negative correlations were observed between the WHO-5 total score, the FAST (r = - 0.46.; p < 0.001) and the HAM-D (r = - 0.68; p < 0.001), but not with the YMRS (r = - 0.07; p = 0.42). Finally, significant differences were found when comparing the WHO-5 total score between patient and healthy controls (t = 5.1; df = 147; p < 0.001). LIMITATIONS: some limitations include the lack of a comparator scale to test for validity construct and the small sample size in the test-retest reliability CONCLUSIONS: The WHO-5 shows an acceptable reliability index and measures a unitary construct in a Spanish population of euthymic patients with BD.


Assuntos
Transtorno Bipolar/psicologia , Transtorno Ciclotímico/psicologia , Testes Psicológicos/normas , Adulto , Feminino , Humanos , Idioma , Masculino , Pessoa de Meia-Idade , Psicometria , Reprodutibilidade dos Testes , Traduções
7.
Braz. j. med. biol. res ; 51(9): e7427, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-951761

RESUMO

Genetic and functional aberrations of guanine nucleotide-binding protein, alpha stimulating (GNAS), aryl hydrocarbon receptor interacting protein (AIP), and pituitary tumor transforming gene (PTTG) are among the most prominent events in pituitary tumorigenesis. A cohort of Brazilian patients with somatotropinomas (n=41) and non-functioning pituitary adenomas (NFPA, n=21) from a single tertiary-referral center were evaluated for GNAS and AIP mutations and gene expression of AIP and PTTG. Results were compared to the clinical and biological (Ki67 and p53 expression) characteristics of tumors and their response to therapy, if applicable. Genetic analysis revealed that 27% of somatotropinomas and 4.8% of NFPA harbored GNAS mutations (P=0.05). However, no differences were observed in clinical characteristics, tumor extension, response to somatostatin analog therapy, hormonal/surgical remission rates, Ki67 index, and p53 expression between mutated and non-mutated somatotropinomas patients. PTTG overexpression (RQ mean=10.6, min=4.39, max=11.9) and AIP underexpression (RQ mean=0.56, min=0.46-max=0.92) were found in virtually all cases without a statistically significant relationship with clinical and biological tumor features. No patients exhibited somatic or germline pathogenic AIP mutations. In conclusion, mutations in GNAS and abnormal PTTG and AIP expression had no impact on tumor features and treatment outcomes in this cohort. Our data support some previous studies and point to the need for further investigations, probably involving epigenetic and transcriptome analysis, to improve our understanding of pituitary tumor behavior.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Neoplasias Hipofisárias/genética , Adenoma/genética , Mutação em Linhagem Germinativa/genética , Adenoma Hipofisário Secretor de Hormônio do Crescimento/genética , Hipófise/patologia , Neoplasias Hipofisárias/patologia , Brasil , DNA de Neoplasias , Marcadores Genéticos , Adenoma/patologia , Transformação Celular Neoplásica , Estudos de Coortes , Peptídeos e Proteínas de Sinalização Intracelular , Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia , Carcinogênese
8.
J Affect Disord ; 221: 205-221, 2017 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-28651185

RESUMO

BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD. Only English-written articles providing original data and focusing in adults with MDD were included with no time restrictions. RESULTS: A total of 95 studies reporting data on 40 pharmacological and non-pharmacological interventions were included. Interventions were grouped into the following categories: 1) Pharmacological Therapies (antidepressants, stimulants, compounds acting on NMDA receptors, compounds acting on the cholinergic system, compounds showing anti-inflammatory or antioxidant properties, other mechanisms of action), 2) Physical Therapies and 3) Psychological Therapies, 4) Exercise. There are some promising compounds showing a positive impact on cognitive symptoms including vortioxetine, lisdexamfetamine or erythropoietin. LIMITATIONS: The studies included showed significant methodological differences in heterogeneous samples. The lack of a standardized neuropsychological battery makes comparisons between studies difficult. CONCLUSION: Current evidence is not sufficient to widely recommend the use of procognitive treatments in MDD although promising results are coming to light.


Assuntos
Disfunção Cognitiva/terapia , Transtorno Depressivo Maior/fisiopatologia , Transtorno Depressivo Maior/terapia , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
9.
J Affect Disord ; 208: 621-627, 2017 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-28029429

RESUMO

BACKGROUND: Cognitive reserve (CR) reflects the capacity of the brain to endure neuropathology, minimize clinical manifestations and successfully complete cognitive tasks. The present study aims to determine whether high CR may constitute a moderator of cognitive functioning in bipolar disorder (BD). METHODS: 102 patients with BD and 32 healthy controls were enrolled. All patients met DSM-IV criteria for I or II BD and were euthymic (YMRS≤6 and HDRS≤8) during a 6-month period. All participants were tested with a comprehensive neuropsychological battery, and a Cerebral Reserve Score (CRS) was estimated. Subjects with a CRS below the group median were classified as having low CR, whereas participants with a CRS above the median value were considered to have high CR. RESULTS: Participants with BD with high CR displayed a better performance in measures of attention (digits forward: F=4.554, p=0.039); phonemic and semantic verbal fluency (FAS: F=9.328, p=0.004; and Animal Naming: F=8.532, p=0.006); and verbal memory (short cued recall of California Verbal Learning Test: F=4.236, p=0.046), after multivariable adjustment for potential confounders, including number of admissions and prior psychotic symptoms. LIMITATIONS: The cross-sectional design of the study does not allow the establishment of causal inferences. Additionally, the small size of the sample may have limited some results. CONCLUSIONS: High cognitive reserve may therefore be a valuable construct to explore for predicting neurocognitive performance in patients with BD regarding premorbid status.


Assuntos
Transtorno Bipolar/psicologia , Reserva Cognitiva , Transtorno Ciclotímico/psicologia , Adulto , Transtorno Bipolar/complicações , Transtornos Cognitivos/psicologia , Estudos Transversais , Sinais (Psicologia) , Transtorno Ciclotímico/complicações , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Adulto Jovem
10.
Biol Sport ; 33(2): 173-7, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-27274111

RESUMO

This report examines the agility and level of acceleration capacity of Spanish soccer referees and investigates the possible differences between field referees of different categories. The speed test consisted of 3 maximum acceleration stretches of 15 metres. The change of direction ability (CODA) test used in this study was a modification of the Modified Agility Test (MAT). The study included a sample of 41 Spanish soccer field referees from the Navarre Committee of Soccer Referees divided into two groups: i) the higher level group (G1, n = 20): 2ndA, 2ndB and 3rd division referees from the Spanish National Soccer League (28.43 ± 1.39 years); and ii) the lower level group (G2, n = 21): Navarre Provincial League soccer referees (29.54 ± 1.87 years). Significant differences were found with respect to the CODA between G1 (5.72 ± 0.13 s) and G2 (6.06 ± 0.30 s), while no differences were encountered between groups in acceleration ability. No significant correlations were obtained in G1 between agility and the capacity to accelerate. Significant correlations were found between sprint and agility times in the G2 and in the total group. The results of this study showed that agility can be used as a discriminating factor for differentiating between national and regional field referees; however, no observable differences were found over the 5 and 15 m sprint tests.

11.
Artigo em Inglês | MEDLINE | ID: mdl-26721949

RESUMO

BACKGROUND: The role of inflammation in mood disorders has received increased attention. There is substantial evidence that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced depression. METHODS: We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase (COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 (FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate analysis. RESULTS: The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history (p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness (p = 0.0200 HR = 1.14), disorderliness (p = 0.0339, HR = 1.11), and low scores on extravagance (p = 0.0040, HR = 0.85). An interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype (HR = 3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) were associated with depression. CONCLUSIONS: The results of the study support the theory that IFN-induced depression is associated with a complex pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden our understanding of the pathogenesis of mood disorders.


Assuntos
Depressão/induzido quimicamente , Depressão/genética , Predisposição Genética para Doença , Interferon-alfa/efeitos adversos , Polimorfismo de Nucleotídeo Único , Adulto , Antivirais/uso terapêutico , Fator Neurotrófico Derivado do Encéfalo/genética , Catecol O-Metiltransferase/genética , Depressão/epidemiologia , Depressão/imunologia , Feminino , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/genética , Hepatite C Crônica/psicologia , Humanos , Incidência , Indolamina-Pirrol 2,3,-Dioxigenase/genética , Interferon-alfa/uso terapêutico , Interferons , Interleucinas/genética , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Receptor 5-HT1A de Serotonina/genética , Receptores de Glucocorticoides/genética , Ribavirina/uso terapêutico , Proteínas de Ligação a Tacrolimo/genética , Resultado do Tratamento , População Branca/genética
12.
Rev. int. med. cienc. act. fis. deporte ; 15(59): 405-418, sept. 2015. tab
Artigo em Espanhol | IBECS | ID: ibc-141695

RESUMO

En este estudio participaron 76 alumnos de 9-10 años de edad de un colegio público de educación primaria (44 chicos y 32 chicas). Los participantes fueron randomizados en función del resultado del pretest en cuatro grupos: interferencia contextual baja (ICB, n=19), interferencia contextual moderada (ICM, n=19) interferencia contextual alta (ICA, n=19) y Grupo Control (GC, n=19). El objetivo de este estudio fue conocer que método de entrenamiento de la agilidad en función de la interferencia contextual baja, moderada o alta (ICB, ICM e ICA) es más efectivo en escolares de cuarto curso de educación primaria, con el fin de dilucidar qué método de desarrollo de esta capacidad resultó el idóneo en esta etapa de escolarización. La agilidad fue evaluada mediante el test MAT2. Salvo en el grupo control (CG), se obtuvieron diferencias significativas en la agilidad (test MAT2), en todos los grupos después de un programa de intervención de 4 semanas de duración en alumnos del cuarto curso de primaria. Estas diferencias han sido superiores en el grupo de ICM (p<0,01, ES=1,12). Se encontraron diferencias significativas (p<0,05, ES=0,79) en el postest entre el grupo de ICM e ICB (AU)


This study involved 76 students from 9-10 years old in a public elementary school (44 boys and 32 girls). Participants were randomized to the outcome of the pretest into four groups: low contextual interference (ICB, n = 19), moderate contextual interference (ICM, n = 19) high contextual interference (ICA, n = 19) and Control Group (GC, n = 19). The aim of this study was to determine which method of agility training (ICB, ICM or ICA) is more effective in primary school children (9-10 years), in order to figure out what method of development of this capacity was the appropriate at this stage of schooling. The agility was evaluated by MAT2 test. Except in the control group (GC), there were significant differences in agility (MAT2 test) in all groups (ICB, ICM and ICA) after an intervention program of 4-week fourth-year students of elementary school. These differences have been higher in the ICM group (p<0.01, ES=1.12). We found significant differences (p<0.05, ES=0.79) in the posttest between the ICM and ICB group (AU)


Assuntos
Criança , Humanos , Destreza Motora/fisiologia , Esportes/fisiologia , Desenvolvimento Infantil/fisiologia , Estudos de Casos e Controles , Deficiências do Desenvolvimento/diagnóstico , 51654/estatística & dados numéricos
13.
Eur Psychiatry ; 30(4): 528-34, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25682181

RESUMO

BACKGROUND: Asenapine is the most recent compound that has been FDA- and EMA-approved for treatment of mania. Its efficacy and safety have been assessed in placebo-controlled trials, but little is known about its performance in routine clinical conditions. In this study, we compared features of patients treated with adjunctive asenapine or other adjunctive antipsychotics and the costs of the treatment. METHODS: A combined prospective and retrospective data collection and analysis was conducted from January 2011 to December 2013 following a clinical interview and assessment of manic and depressive symptoms (YMRS, HDRS-17), clinical state (CGI-BP-M), psychosocial functioning (FAST), sexual dysfunction (PRSexDQ) and health resource costs associated with treatment with adjunctive asenapine versus other adjunctive antipsychotics. RESULTS: Hundred and fifty-two patients from different university hospitals were included. Fifty-three patients received adjunctive asenapine and 99 received other adjunctive antipsychotics concomitantly to mood stabilizers. Considering inpatients, those treated with adjunctive asenapine presented a significantly less severe manic episode (P=0.001), less psychotic symptoms (P=0.030) and more comorbid personality disorder (P=0.002). Regarding outpatients, those treated with adjunctive asenapine showed significantly less severe manic episode (P=0.046), more previous mixed episodes (P=0.013) and more sexual dysfunction at baseline (P=0.036). No significant differences were found in mean total costs per day. CONCLUSION: Clinicians tended to use adjunctive asenapine in patients with less severe manic symptoms but more complex clinical profile, including more mixed episodes in the past, concomitant personality disorder, and sexual problems. Treatment with adjunctive asenapine was not associated with higher costs when compared to other options.


Assuntos
Antipsicóticos/administração & dosagem , Transtorno Bipolar/tratamento farmacológico , Compostos Heterocíclicos de 4 ou mais Anéis/administração & dosagem , Adulto , Transtorno Bipolar/complicações , Depressão/tratamento farmacológico , Dibenzocicloeptenos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais/estatística & dados numéricos , Transtornos da Personalidade/tratamento farmacológico , Estudos Prospectivos , Transtornos Psicóticos/tratamento farmacológico , Estudos Retrospectivos , Resultado do Tratamento
14.
Acta Psychiatr Scand ; 130(5): 354-63, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24961757

RESUMO

OBJECTIVE: We discuss the rationale behind staging systems described specifically for bipolar disorders. Current applications, future directions and research gaps in clinical staging models for bipolar disorders are outlined. METHOD: We reviewed the literature pertaining to bipolar disorders, focusing on the first episode onwards. We systematically searched data on staging models for bipolar disorders and allied studies that could inform the concept of staging. RESULTS: We report on several dimensions that are relevant to staging concepts in bipolar disorder. We consider whether staging offers a refinement to current diagnoses by reviewing clinical studies of treatment and functioning and the potential utility of neurocognitive, neuroimaging and peripheral biomarkers. CONCLUSION: Most studies to date indicate that globally defined late-stage patients have a worse overall prognosis and poorer response to standard treatment, consistent with patterns for end-stage medical disorders. We believe it is possible at this juncture to speak broadly of 'early'- and 'late'-stage bipolar disorder. Next steps require further collaborative efforts to consider the details of preillness onset and intermediary stages, and how many additional stages are optimal.


Assuntos
Transtorno Bipolar/diagnóstico , Comitês Consultivos , Biomarcadores/sangue , Transtorno Bipolar/sangue , Progressão da Doença , Humanos , Índice de Gravidade de Doença , Sociedades Médicas
15.
Acta Psychiatr Scand ; 129(6): 437-44, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24628576

RESUMO

OBJECTIVE: There are several models of staging in bipolar disorder (BD), but none has been validated. The aims of this study were to empirically investigate clinical variables that may be useful to classify patients in clusters according to stage and study the association with biomarkers as biological validators. METHOD: This was a historical cohort study. Patients (n = 115) diagnosed with BD and not in an acute episode and first-degree relatives of patients diagnosed with BD (n = 25) were recruited. Sociodemographic, clinical, and functional data were collected. Serum cytokines, brain-derived neurotrophic factor, and biomarkers of lipid and protein oxidation were assessed. Cluster analysis was carried out to build a model of staging, and logistic regression was conducted to study associations between the model and biomarkers. RESULTS: Cluster analysis divided the sample into two equitable groups, denominated early and late stage, with empirical cutoffs for the Functioning Assessment Short Test score, number of episodes, age at onset of the disorder, and time elapsed since first episode. In the logistic regression, IL-6 was associated with late stage (P = 0.029). CONCLUSION: This study supports that clinical, functional, and biochemical variables may help to define a classification of staging in BD.


Assuntos
Transtorno Bipolar/diagnóstico , Interleucina-6/sangue , Adulto , Idade de Início , Transtorno Bipolar/sangue , Transtorno Bipolar/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Fatores de Tempo
16.
Clín. investig. ginecol. obstet. (Ed. impr.) ; 41(1): 38-41, ene.-mar. 2014. ilus
Artigo em Espanhol | IBECS | ID: ibc-118101

RESUMO

La leiomiomatosis benigna metastatizante (LBM) es una enfermedad muy poco frecuente. Tiene su origen en la proliferación y metástasis del tejido muscular liso, por lo general procedente de un mioma uterino primario. La forma clínica más frecuente es la leiomiomatosis pulmonar benigna que se manifiesta por la presencia de nódulos pulmonares metastásicos sin afectación sistémica .El diagnóstico es histológico, definiéndose por tener bajo grado de mitosis y receptores de estrógenos y progesterona positivos. Es característicamente benigna y hormonodependiente. La finalidad del tratamiento es disminuir el nivel hormonal mediante la inhibición farmacológica y la ooforectomía bilateral. Presentamos un caso de LBM en una paciente de 47 años con diagnóstico de sarcoma del estroma endometrial


Benign metastasizing leiomyomatosis is a highly infrequent entity consisting of the proliferation and metastasis of smooth muscular tissue usually from a primary uterine myoma. The most frequent clinical presentation is benign pulmonary leiomyomatosis, characterized by the presence of metastatic lung nodes with no systemic involvement. Diagnosis is histological, defined by a low grade of mitosis and positive estrogen and progesterone receptors. This entityis typically benign and hormone-dependent. The aim of treatment is to decrease hormone levels through pharmacological inhibition and bilateral oophorectomy. We present a case of benign metastasizing leiomyomatosis in a 47-year-old woman who was diagnosed with endometrial stromal sarcoma


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Leiomiomatose/patologia , Metástase Neoplásica/patologia , Sarcoma do Estroma Endometrial/patologia , Neoplasias Hormônio-Dependentes/patologia , Ovariectomia
18.
Acta Psychiatr Scand ; 129(5): 393-400, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-23957567

RESUMO

OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is consistently associated with acute mood episodes in bipolar disorder, but there is a lack of longitudinal data to support this hypothesis. In this 16-week open-label clinical trial, we tested the predictive role of BDNF Val66Met polymorphism on serum BDNF levels and the relationship of serum BDNF and clinical response in people with bipolar disorder during an acute illness episode. METHOD: Sixty-four people with bipolar disorder who were medication-free at baseline and in an acute mood episode were recruited. They were matched with 64 healthy controls. Clinical evaluation, serum BDNF, and BDNF Val66Met polymorphism were determined at baseline, and change in serum BDNF was assessed in patients at weeks 2, 4, 8 and 16. RESULTS: There were no differences between patients and controls in serum BDNF or in frequencies of the BDNF Val66Met polymorphism genotype at baseline. The multivariable model showed that Met carriers had a significantly different change in BDNF levels compared with Val homozygotes. Not achieving a complete remission was also associated with lower prospectively assessed BDNF levels. CONCLUSION: This study provides the first longitudinal evidence that both the BDNF Val66Met polymorphism and remission status predict change in circulating BDNF levels.


Assuntos
Sintomas Afetivos , Transtorno Bipolar , Fator Neurotrófico Derivado do Encéfalo , Psicotrópicos/farmacologia , Adulto , Afeto/fisiologia , Sintomas Afetivos/sangue , Sintomas Afetivos/diagnóstico , Sintomas Afetivos/genética , Substituição de Aminoácidos/genética , Biomarcadores/sangue , Transtorno Bipolar/sangue , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/genética , Transtorno Bipolar/psicologia , Fator Neurotrófico Derivado do Encéfalo/sangue , Fator Neurotrófico Derivado do Encéfalo/genética , Brasil , Monitoramento de Medicamentos/métodos , Feminino , Humanos , Estudos Longitudinais , Masculino , Metionina/genética , Plasticidade Neuronal , Gravidade do Paciente , Polimorfismo Genético , Escalas de Graduação Psiquiátrica , Valina/genética
19.
Biol Sport ; 30(2): 91-5, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24744473

RESUMO

The aim of the present study was to analyse the parameters that characterize the vertical ground reaction force during the landing phase of a jump, and to determine the relationship among these parameters in elite soccer players with cerebral palsy (CP). Thirteen male members of the Spanish national soccer team for people with CP (mean age: 27.1 ± 4.7 years) volunteered for the study. Each participant performed three counter movement jumps. The characteristics of the first peak of the vertical ground reaction force during the landing phase of a jump, which corresponds to the forefoot contact with the ground, were similar to the results obtained in previous studies. However, a higher magnitude of rearfoot contact with the ground (F2) was observed in participants with CP than in participants without CP. Furthermore, a significant correlation between F2 magnitude and the elapsed time until its production (T2) was not observed (r = -0.474 for p = 0.102). This result implies that a landing technique based on a delay in the production of F2 might not be effective to reduce its magnitude, contrary to what has been observed in participants without CP. The absence of a significant correlation between these two parameters in the present study, and the high magnitude of F2, suggest that elite soccer players with CP should use footwear with proper cushioning characteristics.

20.
Acta Psychiatr Scand ; 127(5): 403-11, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-22924855

RESUMO

OBJECTIVE: Patients diagnosed with bipolar disorder (BD) are reported to have significant work impairment during interepisode intervals. This study was carried out to assess potential predictors of occupational disability in a longitudinal follow-up of euthymic patients. METHOD: We included 327 euthymic patients diagnosed with BD type I or type II, 226 of whom were employed and 101 were receiving a severe disablement benefit (SDB). Sociodemographic data were studied and episode recurrence was assessed along a 1-year follow-up. Logistic regression analysis was applied to determine predictors of receiving SDB. Cox regression was built to study recurrences. RESULTS: Predictors of receiving SDB were: axis II comorbidity [Odds Ratio (OR) = 2.94, CI: 1.26-6.86, P = 0.013], number of manic episodes (OR = 1.21, CI: 1.10-1.34, P < 0.001), being without stable partner (OR = 2.44, CI: 1.34-4.44, P = 0.004) and older age (OR = 1.08, CI: 1.05-1.12, P < 0.001). Bipolar patients receiving SDB presented more episodic recurrences regardless of polarity than employed bipolar patients (P = 0.002). The time until recurrence in 25% of the bipolar patients receiving SDB was 6.08 months (CI: 4.44-11.77) being 13.08 months (CI: 9.60 to -) in the employed group. CONCLUSION: Occupational disability in bipolar patients is associated with axis II comorbidity, more previous manic episodes, not having a stable relationship, older age, and more recurrences at 1-year follow-up.


Assuntos
Transtorno Bipolar/epidemiologia , Pessoas com Deficiência/psicologia , Adulto , Transtorno Bipolar/psicologia , Pessoas com Deficiência/estatística & dados numéricos , Emprego/psicologia , Emprego/estatística & dados numéricos , Feminino , Seguimentos , Humanos , Modelos Logísticos , Estudos Longitudinais , Masculino , Modelos de Riscos Proporcionais , Recidiva , Fatores de Risco , Espanha/epidemiologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...